SANTA CLARA, Calif., Nov. 22, 2010 -- Agilent Technologies Inc. (NYSE: A) today announced that Merck-Serono, a division of Merck KGaA, Darmstadt, Germany, has selected the Agilent OpenLAB Electronic Lab Notebook (ELN) to enhance scientific collaboration globally throughout R&D for finding new small molecules and biopharmaceuticals.
While financial details were not disclosed, approximately 600 Merck-Serono biology researchers at facilities in Geneva, Darmstadt and Boston will be using the Agilent OpenLAB ELN to collaborate on research projects.
“The Agilent partnership with Merck-Serono illustrates the strength of OpenLAB ELN as a collaboration platform protecting research IP,” said Bruce von Herrmann, vice president and general manager, Agilent Software and Informatics. “It is gratifying to work with their researchers -- across multiple scientific disciplines -- with tools to build a knowledge base integrated into their overall discovery system landscape.”
OpenLAB ELN features the ability to design and customize experiment templates that enable scientists to create, share and reuse these templates. Additionally, scientists can create an experimental desktop according to their preferences and work practices.
Other benefits of OpenLAB ELN include delegation workflows and audit trails. Delegation workflows facilitate enterprise-wide collaboration, as multiple scientists can collaborate on a single experiment, entering data and results from multiple techniques on a single sample or multiple samples. The audit trails maintain an environment that delivers the highest level of intellectual property protection.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company’s 18,500 employees serve customers in more than 100 countries. Agilent had net revenues of $5.4 billion in fiscal 2010. Information about Agilent is available at www.agilent.com.
